

A Big Pharma "Delinking" Bailout Is the Top Priority for the Pharmaceutical Industry

Drug Companies Are Behind the Very "Delinking" Legislation That Would Hand Big Pharma a \$32 Billion Bailout Paid for by Patients, Taxpayers, and Health Plan Sponsors

Congress is considering misguided proposals targeting the market-based role of pharmacy benefit companies in the health care system. Pharmacy benefit companies are securing savings for patients, taxpayers, and health plan sponsors, like small businesses — and serving as the only real check on the otherwise unlimited pricing power of Big Pharma, by leveraging scale to negotiate price concessions from big drug companies through rebates.

It's no surprise that the entity behind the "delinking" legislation that would hand Big Pharma a whopping \$32 billion bailout annually is Big Pharma itself.

Big Pharma's Push for Multi-Billion-Dollar "Delinking" Bailout Started Years Ago:

Cathy Kelly, 7/16/18

PINK SHEET
CITELINE REGULATORY

Beyond Rebates: PhRMA Wants HHS To 'De-Link' Supply Chain Compensation From List Price Focus should not be limited to rebates in Medicare Part D, manufacturers advise in comments on HHS drug pricing blueprint.

PhRMA Letter to HHS, 7/16/18

P/RMA

"[...] We suggest that any reforms of the safe harbors be undertaken with the goal of delinking compensation based on list price (including both fees and rebates) throughout the supply chain, and not focus solely on rebates."

PhRMA, 7/16/18

P/RMA

Biopharmaceutical Industry Takes Bold New Policy Position On How Payments Should Work In Supply Chain



"Delinking" Is Now An Integral Part of Big Pharma's Policy Agenda:

Susan Morse, 9/18/23

HEALTHCARE FINANCE

PhRMA, 9/18/23

P/RMA

PBMs Are Driving Up Drug Prices Through Fees, PhRMA Report Claims

"[...] PhRMA recommends that PBM compensation no longer be tied to the price of medicines and that they should instead receive a flat fee." "[...] Congress has an unprecedented opportunity to help strengthen market competition and provide meaningful relief to patients and taxpayers. That starts with breaking the link between PBM compensation and the price of medicines."

PhRMA's Building a Better Health Care System Policy Platform:

Fostering Competition



Ending perverse incentives by tying the fees pharmaceutical supply chain middlemen charge to the services they provide, not the list price of a medicine, and fostering the competitive market for medicines while also providing needed incentives for continued biopharmaceutical innovation.



Middlemen's business model can lead to higher costs for everyone.

Middlemen say they want lower prices, yet they often deny or limit coverage of lower-cost generics and biosimilars. That's because PBMs are charging fees tied to the price of medicines, which means they make more money when the price of medicine goes up. This allows PBM profits to soar and experts warn it can lead to higher costs for everyone.


Learn More >

PhRMA's "Middlemen" Landing Page

Big Pharma Urges Congress to Pass Billion-Dollar "Delinking" Bailout:

PhRMA Take Action Page:

URGE YOUR SENATORS TO STAND UP TO DRUG	Urge Your Senators to Stand Up to Drug Middlemen and Cosponsor S. 1542 Title Transfer Transfe
MIDDLEMEN AND COSPONSOR S. 1542	*Last None * Last None * Address * Zp * Phone
Lawmakers are working on bipartison legislation that addresses same of the abusive practices pharmacy benefit managers (PBMe) use to pod their profits at the expense of patients. PBMs work with insurance companies to de	* Email * Sand mail should this compaign SEND EMAIL
We need your help to keep up the pressure on Congress to pass strong PBM reform this year.	© 2023. All rights reserved. Subject to Phropsy Policy



Other PhRMA-Backed Groups Are Running "Delinking" Ads:

PBM Accountability Project, funded by drug companies





BIO, another drug company trade association

Shine a light on shady PBM practices.

Tell Congress to pass PBM Reform